These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

995 related items for PubMed ID: 15810910

  • 1. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators.
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [Abstract] [Full Text] [Related]

  • 2. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Young G, Cooper DL, Gut RZ, HTRS Investigators.
    Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
    [Abstract] [Full Text] [Related]

  • 3. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL, Htrs Investigators.
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [Abstract] [Full Text] [Related]

  • 4. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [Abstract] [Full Text] [Related]

  • 5. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA, Cooper DL, Goldstein B.
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [Abstract] [Full Text] [Related]

  • 6. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL.
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [Abstract] [Full Text] [Related]

  • 7. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B, Wiis J.
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [Abstract] [Full Text] [Related]

  • 8. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
    Gruppo RA, Kessler CM, Neufeld EJ, Cooper DL.
    Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
    [Abstract] [Full Text] [Related]

  • 9. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
    Nakar C, Cooper DL, DiMichele D.
    Haemophilia; 2010 Jul 01; 16(4):625-31. PubMed ID: 20158526
    [Abstract] [Full Text] [Related]

  • 10. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut RZ, Cooper DL.
    Haemophilia; 2014 Jan 01; 20(1):e23-31. PubMed ID: 24354484
    [Abstract] [Full Text] [Related]

  • 11. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Neufeld EJ, Saxena K, Kessler CM, Cooper DL, HTRS Investigators.
    Pediatr Blood Cancer; 2013 Jul 01; 60(7):1178-83. PubMed ID: 23335449
    [Abstract] [Full Text] [Related]

  • 12. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec 01; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 13. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
    Seremetis S.
    Blood Coagul Fibrinolysis; 2003 Jun 01; 14 Suppl 1():S29-30. PubMed ID: 14567532
    [Abstract] [Full Text] [Related]

  • 14. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I, Klamroth R, Eichler H, Schenk J, Kirchmaier CM, Halimeh S.
    Haemophilia; 2013 Sep 01; 19(5):679-85. PubMed ID: 23647644
    [Abstract] [Full Text] [Related]

  • 15. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP.
    Pathophysiol Haemost Thromb; 2002 Sep 01; 32 Suppl 1():22-5. PubMed ID: 12214142
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V.
    Haemophilia; 2007 Sep 01; 13(5):502-7. PubMed ID: 17880436
    [Abstract] [Full Text] [Related]

  • 17. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U, Livnat T, Zivelin A, Kenet G.
    Haemophilia; 2009 Jul 01; 15(4):904-10. PubMed ID: 19473416
    [Abstract] [Full Text] [Related]

  • 18. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul 01; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 19. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G, Shafer FE, Rojas P, Seremetis S.
    Haemophilia; 2008 Mar 01; 14(2):287-94. PubMed ID: 18081834
    [Abstract] [Full Text] [Related]

  • 20. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
    Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, Cetkovsky P, Dusek L, Hedner U.
    Haemophilia; 2009 May 01; 15(3):752-9. PubMed ID: 19432926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.